Van Damme P - Search Results

1

Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium.

Wouters K, Leuridan E, Van Herck K, Van Ardenne N, Roelofs I, Mak R, Prévost C, Guérin P, Denis B, Van Damme P. Wouters K, et al. Among authors: van ardenne n, van damme p, van herck k. Vaccine. 2007 Feb 26;25(10):1893-900. doi: 10.1016/j.vaccine.2006.09.073. Epub 2006 Oct 9. Vaccine. 2007. PMID: 17239492 Clinical Trial.

2

Cost-effectiveness analysis of hepatitis A prevention in travellers.

Tormans G, Van Damme P, Van Doorslaer E. Tormans G, et al. Among authors: van doorslaer e, van damme p. Vaccine. 1992;10 Suppl 1:S88-92. doi: 10.1016/0264-410x(92)90554-w. Vaccine. 1992. PMID: 1335668

3

Heat stability of a recombinant DNA hepatitis B vaccine.

Van Damme P, Cramm M, Safary A, Vandepapelière P, Meheus A. Van Damme P, et al. Vaccine. 1992;10(6):366-7. doi: 10.1016/0264-410x(92)90064-q. Vaccine. 1992. PMID: 1534639 Clinical Trial.

4

Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome.

Van Damme P, Vranckx R, Meheus A. Van Damme P, et al. Vaccine. 1990 Mar;8 Suppl:S53-5; discussion S60-2. doi: 10.1016/0264-410x(90)90236-f. Vaccine. 1990. PMID: 2139285 Clinical Trial.

5

Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients.

Van Damme P, Vranckx R, Safary A, André FE, Meheus A. Van Damme P, et al. Am J Med. 1989 Sep 4;87(3A):26S-29S. doi: 10.1016/0002-9343(89)90527-5. Am J Med. 1989. PMID: 2528294

6

Hepatitis B prevention in Europe: a preliminary economic evaluation.

Van Damme P, Tormans G, Beutels P, Van Doorslaer E. Van Damme P, et al. Among authors: van doorslaer e. Vaccine. 1995;13 Suppl 1:S54-7. doi: 10.1016/0264-410x(95)93549-o. Vaccine. 1995. PMID: 7571833 Free article.

7

Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity.

Van Damme P, Matheï C, Thoelen S, Meheus A, Safary A, André FE. Van Damme P, et al. J Med Virol. 1994 Dec;44(4):435-41. doi: 10.1002/jmv.1890440422. J Med Virol. 1994. PMID: 7897376 Clinical Trial.

8

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.

Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Van Damme P, et al. J Med Virol. 1994 Dec;44(4):446-51. doi: 10.1002/jmv.1890440425. J Med Virol. 1994. PMID: 7897379 Clinical Trial.

9

Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium.

Tormans G, Van Damme P, Carrin G, Clara R, Eylenbosch W. Tormans G, et al. Among authors: van damme p. Soc Sci Med. 1993 Jul;37(2):173-81. doi: 10.1016/0277-9536(93)90453-b. Soc Sci Med. 1993. PMID: 8351532

10

Hepatitis B vaccine administration: comparison between jet-gun and syringe and needle.

Matheï C, Van Damme P, Meheus A. Matheï C, et al. Among authors: van damme p. Vaccine. 1997 Mar;15(4):402-4. doi: 10.1016/s0264-410x(96)00196-x. Vaccine. 1997. PMID: 9141211 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,260 results

Search Page

Filters